Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF) (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Depreciation & Amortization (CF) data on record, last reported at $832000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 9.33% year-over-year to $832000.0; the TTM value through Dec 2025 reached $3.3 million, up 8.85%, while the annual FY2025 figure was $3.3 million, 6.79% up from the prior year.
  • Depreciation & Amortization (CF) reached $832000.0 in Q4 2025 per FHTX's latest filing, up from $773000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $900000.0 in Q3 2022 and bottomed at $700000.0 in Q3 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $824350.0, with a median of $805500.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 300.0% in 2021, then decreased 22.22% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $800000.0 in 2021, then grew by 6.0% to $848000.0 in 2022, then increased by 6.13% to $900000.0 in 2023, then fell by 15.44% to $761000.0 in 2024, then rose by 9.33% to $832000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $832000.0 in Q4 2025, $773000.0 in Q3 2025, and $900000.0 in Q2 2025.